Teva's Research And Medical Chief Leaves His Role After Accepting An Outside Offer
Teva kept its $6–7 billion innovative-medicines revenue ambition for 2030 as it began searching for a permanent successor.
Teva Pharmaceutical Industries, which makes generic and brand-name medicines, announced Wednesday that its research and medical chief, Eric Hughes, had stepped down immediately, according to its SEC filing. Hughes accepted an outside offer, the company said in its release, but will stay through the coming months to help transfer his responsibilities.
The $6–7 Billion Ambition Stays
Teva retained its ambition to produce $6–7 billion in innovative-medicines revenue by 2030. That goal was among the development commitments it outlined at its November 11 R&D Day.
Richard Francis, Teva's president and chief executive, said: "Our strategy, priorities and expectations have not changed." He credited Hughes with helping build the drug pipeline, research capabilities and organization presented at the event.
Teva's Pivot to Growth strategy calls for expanding its innovative-medicines pipeline and its biosimilars business—medicines highly similar to existing biological drugs. The revenue figure remains an ambition for that innovative portfolio.
Gardiner Takes The Transition Lead
David Gardiner, who heads Innovative Medicines & Clinical Development, became research transition lead immediately. He reports directly to Francis until Teva names a permanent successor.
Hughes notified Teva Tuesday that he intended to resign as executive vice president for global research and development and chief medical officer. His departure from those roles and his continued work on the handover are distinct parts of the transition.
Research Beyond The Generics Business
Teva's brand-name business focuses on brain and nervous system conditions, including migraine, multiple sclerosis and movement disorders. Its broader product portfolio includes generic medicines, biosimilars and over-the-counter products.
The company operates across the United States, Europe and International Markets. Most of its U.S. generic sales go through retail drug chains, mail-order distributors and wholesalers; its Anda unit distributes medicines to pharmacies, hospitals and physician offices.
Teva also sells active pharmaceutical ingredients and offers contract manufacturing. The research leadership change comes within a business that combines those operations with its plans to expand innovative medicines.
Teva is beginning its search for a permanent research and medical chief; Gardiner will lead the research transition in the meantime.
Sources
- 8-K Filing — TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) — SEC EDGAR
- Exhibit teva-ex99_1.htm — TEVA PHARMACEUTICAL INDUSTRIES LTD 8-K exhibit — SEC EDGAR
- Teva Announces R&D Leadership Transition; Eric Hughes to — globenewswire.com